144 related articles for article (PubMed ID: 20408429)
1. [A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
Arushanian EB
Eksp Klin Farmakol; 2010 Mar; 73(3):35-9. PubMed ID: 20408429
[TBL] [Abstract][Full Text] [Related]
2. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
3. [Epiphyseal hormone melatonin: a new nootrope?].
Arushunian EB
Eksp Klin Farmakol; 2005; 68(3):74-9. PubMed ID: 16047688
[No Abstract] [Full Text] [Related]
4. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2010 Mar; 8(91):19-24. PubMed ID: 20179667
[No Abstract] [Full Text] [Related]
5. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.
Senin U; Cherubini A; Palumbo B; Mecocci P
Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980
[No Abstract] [Full Text] [Related]
6. Cognitive issues in Parkinson's disease.
Elmer L
Neurol Clin; 2004 Oct; 22(3 Suppl):S91-S106. PubMed ID: 15501368
[No Abstract] [Full Text] [Related]
7. A case study in the treatment of dementia with Lewy bodies.
Kaufer DI
Acta Psychiatr Scand; 2004 Jul; 110(1):73-5; discussion 75-6. PubMed ID: 15180783
[TBL] [Abstract][Full Text] [Related]
8. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
Willis GL; Robertson AD
Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
[TBL] [Abstract][Full Text] [Related]
9. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
10. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
Fariello RG
Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
[No Abstract] [Full Text] [Related]
11. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacologic treatment for cognitive disorders: an update].
Lestage P
Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
[TBL] [Abstract][Full Text] [Related]
13. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
Tariska P; Paksy A
Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
[TBL] [Abstract][Full Text] [Related]
14. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Willis GL; Robertson AD
Pharmacol Biochem Behav; 2004 Nov; 79(3):413-29. PubMed ID: 15582013
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Parnetti L; Mignini F; Tomassoni D; Traini E; Amenta F
J Neurol Sci; 2007 Jun; 257(1-2):264-9. PubMed ID: 17331541
[TBL] [Abstract][Full Text] [Related]
16. Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
Wesnes KA; McKeith I; Edgar C; Emre M; Lane R
Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500
[TBL] [Abstract][Full Text] [Related]
17. Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent.
Cardinali DP; Furio AM; Reyes MP
Ann N Y Acad Sci; 2005 Dec; 1057():327-36. PubMed ID: 16399904
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
[TBL] [Abstract][Full Text] [Related]
19. [The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].
Horváth S
Orv Hetil; 2001 Feb; 142(8):383-9. PubMed ID: 11263076
[TBL] [Abstract][Full Text] [Related]
20. [Nootropic drugs: definition, classification, mechanism of action, clinical effectiveness, substances].
Kuhlmey J
Z Arztl Fortbild (Jena); 1994 Sep; 88(9):697-701. PubMed ID: 7975756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
